Reduce the annulus.
Reduce mitral regurgitation.
Mitral regurgitation: Complex treatment with limited options.

Mitral regurgitation occurs in approximately 2% of the global population, with up to 10% of people over 75 years old affected.¹

Medically managed patients with severe MR have poor outcomes:²

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality rate²</td>
<td>Proportion of surviving patients hospitalised for heart failure²</td>
</tr>
<tr>
<td>20%</td>
<td>50%</td>
</tr>
<tr>
<td>41%</td>
<td>90%</td>
</tr>
</tbody>
</table>
A CE-mark approved transcatheter device designed to safely and effectively reduce mitral regurgitation through annular reduction.³

- Restores valve to a more functional state, facilitating leaflet coaptation
- Enables annular reduction based on each patient’s anatomy
- Supports real-time confirmation of procedural results
Adjust annular dimension. Confirm real-time results.

Precise positioning in patient anatomy

- Supra-annular fixation preserves the native anatomy and does not limit subsequent treatment
- Radiopaque markers facilitate navigation and support precise anchor positioning
- Polyester sleeve secures the attaching anchors within the implant
- Size-adjustment mechanism allows for a homogeneous annular reduction

Real-time confirmation of results

Pre-procedure

Adjust and confirm MR reduction in real time
A reproducible and standardised procedure.

1. Access

Insert Cardioband delivery system into the left atrium using a transseptal approach.

2. Deploy

Deploy implant via a steerable catheter designed to reach any point of the annulus. Connect the implant along the posterior annulus with stainless steel anchors.

3. Adjust and reduce MR

Introduce the size-adjustment tool over a wire. Turn roller for annular adjustment and leaflet coaptation.
Reduce the annulus.
Restore her potential.

For more information, please visit www.Edwards.com/CardiobandMR
Reduce the annulus.
Reduce mitral regurgitation.

• A CE-Mark approved transcatheter solution to effectively reduce mitral regurgitation through annular reduction
• Enables annular reduction based on each patient’s anatomy
• Supports real-time confirmation of procedural results
• Shows significant and durable improvement in patient outcomes

Driven by a passion to help patients.

With over 60 years of experience in creating new therapies and procedures that elevate care in meaningful ways, Edwards Lifesciences is the global leader in patient-focused medical innovations.

For more information, please visit www.Edwards.com/CardiobandMR

References

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity. Cardioband is manufactured by Valtech Cardio Ltd for Edwards Lifesciences.

Edwards, Edwards Lifesciences, the stylized E logo, and Cardioband are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2018 Edwards Lifesciences Corporation. All rights reserved. E7878/02-18/TMTT
Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com